NovaBay Pharmaceuticals And Sonoma Pharmaceuticals Agree To Market Avenova-Branded Products In European Union; Sonoma Will Manufacture Ocudox And Pay NovaBay Royalty Fee Based On Net Product Sales
NovaBay Pharmaceuticals And Sonoma Pharmaceuticals Agree To Market Avenova-Branded Products In European Union; Sonoma Will Manufacture Ocudox And Pay NovaBay Royalty Fee Based On Net Product Sales
NovaBay Pharmicals 和 Sonoma Pharmicals 同意在歐盟銷售 Avenova 品牌的產品；索諾瑪將生產 Ocudox 並根據產品淨銷售額支付 NovaBay 特許權使用費
The new products will combine Sonoma's existing eye product Ocudox, which has already received a Class IIB CE mark for sale in the European Union, with Avenova branding, and are expected to be marketed through Sonoma's established European distribution network. This agreement brings together NovaBay's deep knowledge of eye care reflected in its Avenova brand with Sonoma's expertise in distributing hypochlorous acid products overseas.
新產品將把索諾瑪現有的眼部產品Ocudox（已獲得在歐盟銷售的IIB CE標誌）與Avenova品牌相結合，預計將通過索諾瑪現有的歐洲分銷網絡進行銷售。該協議彙集了NovaBay在其Avenova品牌中體現的深厚眼部護理知識和索諾瑪在海外分銷次氯酸產品的專業知識。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。